Salbutamol 4 mg

• Salbutamol 4 mg
• Brand: Magnus Pharmaceuticals
• Content: 100 tablets | 4 mg per tablet
• Manufactured in: Europe

Product Overview

Salbutamol 4 mg delivers a fast-acting 2-adrenergic agonist commonly used in airway research and cardiopulmonary modeling. Known in the U.S. as albuterol, this compound supports investigations into bronchodilation, exercise-induced asthma mitigation, airway-smooth-muscle signaling, and fat-loss models tied to 2 stimulation.

With onset in ~30 minutes and duration of 4–6 hours, oral salbutamol enables dynamic testing across acute and chronic studies. A 5–6 hour half-life supports twice-daily dosing in respiratory-performance trials, and its oral form simplifies lab handling over inhaler-based delivery.

Key Research Highlights

• Potent bronchodilation: 4 mg oral dose improves FEV and FVC in mild asthma cohorts within 30 minutes [PubMed]
• Respiratory-performance models: Improved inspiratory capacity and reduced residual lung volume documented in exercise-based studies [PubMed]
• Systemic activity:Promotes intracellular potassium shift and raises heart rate — relevant for cardiometabolic modeling [Mayo Clinic]
• Anti-doping relevance: WADA bans all oral forms; only inhaled 1,600 µg/day permitted — tablet exposure triggers positive test [wada-ama.org]
• Room-temperature stable: Film-coated tablets retain potency at 25 °C for 36 months — better shelf life than inhaler solutions [nhs.uk]

Suggested Laboratory Applications

Bronchodilation and airway-smooth-muscle pharmacology

Exercise-induced asthma and VO-max modeling

2-agonist thermogenic & fat-loss studies

Hypokalaemia and systemic electrolyte tracking

Cardiopulmonary performance and heart-rate stress simulations

Technical Specifications

Detection Window

24 hours (oral), varies by dose

Documented Benefits

FEV, airway resistance, VO-max, thermogenic modeling

Main Risks

Tremor, tachycardia, hypokalaemia, insomnia, bronchospasm

Total Active Compound

400 mg per carton (4 mg 100 tablets)

Shelf-life

36 months (manufacturer specification)

PubChem-Supported Research Insights

Promotes rapid bronchodilation in obstructive lung models

Improves peak expiratory metrics (FEV, FVC) in dose-dependent trials

Shown to increase cardiac output and VO-max in heart-failure studies

Studied for thermogenic/lipolytic effects in 2-stimulation models

Oral route supports longer systemic effect and steady sampling

Documented Research Side Effects

Common: Tremor, headache, insomnia, and tachycardia

Dose-related: Hypokalaemia due to potassium shift

Rare: Paradoxical bronchospasm during airway-sensitive protocols

Cardiovascular strain at elevated exposure

Handling & Compliance

For Research Use Only — Not for human or veterinary useStore at 15–25°C, protect from light and moisturePurchase confirms qualified researcher statusListed under WADA S3 (2-agonists) — oral exposure prohibited without TUE